Market Snapshot: Shenzhen Mindray Bio‑Medical on 20 October 2026
At 20 October 2026, Shenzhen Mindray Bio‑Medical (ticker 300760.SZ) closed the trading day unchanged, with the price holding at CNY 169.76 on the main Chinese exchanges. The shares were quoted at a 24‑hour volume of CNY 1.5 billion, a modest rise of 6.01 % since the end of last month. With a market capitalisation of CNY 202.3 billion and a public float of approximately 1.2 billion shares, the company remains a significant component of the A‑share medical‑equipment sector.
The stock’s 200‑day simple moving average stands at CNY 152.70, placing it well above its 52‑week low of CNY 130.66 (recorded on 29 June 2026) and comfortably below the peak of CNY 226.36 reached on 28 October 2025. This technical profile suggests a bullish bias, with the current price tracking comfortably above the medium‑term trend line.
Corporate Context
Shenzhen Mindray Bio‑Medical Electronics Co. Ltd. was founded in 1991 and is headquartered in Shenzhen. The company is a subsidiary of Mindray Medical International Limited and offers a comprehensive portfolio of medical equipment and consumables, including:
- Patient monitoring systems (cardio‑pulmonary, anesthesia, intensive‑care units)
- Life‑support devices (ventilators, defibrillators, infusion pumps)
- Diagnostic instruments (hematology, chemistry, immunoassay analyzers, flow cytometers)
- Imaging solutions (ultrasound, radiology)
- Veterinary products
The firm’s broad product mix positions it well to capture demand across both clinical and critical‑care markets, while its IT and data‑analytics capabilities support the growing trend toward connected, AI‑enhanced monitoring.
Recent Market Activity
While Shenzhen Mindray’s price remained flat over the 24‑hour window, the traded volume of CNY 1.5 billion indicates continued investor interest. The price‑to‑earnings ratio is currently not disclosed, but the company’s earnings guidance for the upcoming quarter reflects steady revenue growth, driven by expanding deployment of its monitoring platforms in hospitals worldwide.
The recent market study on capnography devices cited Shenzhen Mindray as a key supplier. The report projects a steady growth trajectory for the global capnography market over the next five years, underpinned by:
- Expanding use in respiratory and cardiac care
- Shift toward portable, wireless monitoring
- Increased investment in AI‑enabled respiratory diagnostics
Mindray’s role in providing both hardware and consumables aligns with this trend, positioning it to benefit from the broader move toward integrated, data‑driven monitoring solutions.
Peer Comparison (24‑Hour Performance)
| Company | Ticker | 24‑Hour % Move | Current Price | Market Cap | Notable Insight |
|---|---|---|---|---|---|
| Wus Printed Circuit Kunsha | 002463.SZ | 0 % | CNY 111.01 | CNY 218.2 billion | Positive Q3 outlook, AI‑server demand |
| Muyuan Foods –H | 2714.HK | +3.08 % | HKD 35.90 | HKD 271.4 billion | Pork price pressure, margin squeeze |
| Bank of Ningbo | 002142.SZ | 0 % | CNY 34.79 | CNY 235.6 billion | Stable earnings, dividend focus |
| Suzhou TFC Optical Communi | 300394.SZ | 0 % | CNY 204.54 | CNY 232.1 billion | Share‑repurchase plan |
| China Pacific Insurance Gr‑H | 2601.HK | –0.9 % | HKD 26.08 | HKD 254.6 billion | Q3 results announcement |
Shenzhen Mindray’s flat performance sits comfortably within a broader A‑share context that has seen mixed movements among peers in the technology and healthcare sectors.
Forward Outlook
Analysts project that Shenzhen Mindray will continue to leverage its diversified product line to capture market share in both domestic and international arenas. The company’s ongoing investments in AI and data‑analytics for patient monitoring are expected to enhance product differentiation and open new revenue streams. Market participants should monitor upcoming earnings releases and the company’s progress in expanding its capnography and critical‑care portfolios, as these developments will likely shape investor sentiment in the near term.
In sum, while the share price has held steady, Shenzhen Mindray Bio‑Medical remains a company of interest for investors seeking exposure to a well‑established player in the evolving landscape of medical‑equipment and digital health solutions.
